Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo

被引:150
作者
Hein, Travis W. [2 ]
Singh, Uma [1 ]
Vasquez-Vivar, Jeannette [3 ,4 ]
Devaraj, Sridevi [1 ]
Kuo, Lih [5 ]
Jialal, Ishwarlal [1 ]
机构
[1] Univ Calif, Davis Med Ctr, Dept Med Pathol & Lab Med, Lab Atherosclerosis & Metab Res, Sacramento, CA 95817 USA
[2] Scott & White Mem Hosp & Clin, Coll Med, Texas A&M Hlth Sci Ctr, Dept Surg, Temple, TX 76508 USA
[3] Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA
[4] Med Coll Wisconsin, Free Rad Res Ctr, Milwaukee, WI 53226 USA
[5] Texas A&M Hlth Sci Ctr, Coll Med, Dept Syst Biol & Translat Med, Temple, TX USA
基金
美国国家卫生研究院;
关键词
CRP; Vasoreactivity; Endothelial nitric oxide synthase; Tetrahydrobiopterin; NADPH oxidase; NITRIC-OXIDE SYNTHASE; ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY-DISEASE; E-DEFICIENT MICE; CARDIOVASCULAR-DISEASE; NAD(P)H OXIDASE; MEDIATED DILATION; NO SYNTHASE; TETRAHYDROBIOPTERIN; SUPEROXIDE;
D O I
10.1016/j.atherosclerosis.2009.02.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and objective: Elevated C-reactive protein (CRP) levels are associated with increased cardiovascular events and endothelial dysfunction. We have previously shown that CRP decreases endothelial nitric oxide synthase (eNOS) activity in endothelial cells and inhibits endothelium-de pendent nitric oxide (NO)-mediated vasodilation in vitro. Herein, we examined the effect of in vivo administration of CRP on endothelial function and underlying mechanisms in a valid animal model. Methods: Sprague-Dawley rats were injected intraperitoneally daily for 3 days with human CRP or human serum albumin (HuSA) at 20 mg/kg body weight. On day 4, mesenteric arterioles were isolated and pressurized for vasomotor study and aortic tissue was subjected to biochemical and molecular analysis. Results: Dilation of mesenteric arterioles to acetylcholine but not to sodium nitroprusside was significantly reduced following CRP treatment. The eNOS activity, eNOS dimer/monomer ratio, tetrahydrobiopterin levels, and protein expression of GTPCH1 were significantly lower in aortic tissue homogenates from CRP-treated than HuSA-treated rats. CRP treatment also resulted in increased dihydroethidium staining for superoxide in aortic endothelium and membrane translocation of p47phox, a regulatory subunit of NADPH oxidase. Conclusion: Our data provide novel evidence for the detrimental action of CRP in vivo by impairing eNOS-dependent vasodilation and uncoupling of eNOS. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:61 / 68
页数:8
相关论文
共 46 条
[21]   INTERACTION OF PRESSURE-INDUCED AND FLOW-INDUCED RESPONSES IN PORCINE CORONARY RESISTANCE VESSELS [J].
KUO, L ;
CHILIAN, WM ;
DAVIS, MJ .
AMERICAN JOURNAL OF PHYSIOLOGY, 1991, 261 (06) :H1706-H1715
[22]   Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension [J].
Landmesser, U ;
Dikalov, S ;
Price, SR ;
McCann, L ;
Fukai, T ;
Holland, SM ;
Mitch, WE ;
Harrison, DG .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (08) :1201-1209
[23]   Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease [J].
Maier, W ;
Cosentino, F ;
Lütolf, RB ;
Fleisch, M ;
Seiler, C ;
Hess, OM ;
Meier, B ;
Lüscher, TF .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2000, 35 (02) :173-178
[24]   FcγRIIB mediates C-reactive protein inhibition of endothelial NO synthase [J].
Mineo, C ;
Gormley, AK ;
Yuhanna, IS ;
Osborne-Lawrence, S ;
Gibson, LL ;
Hahner, L ;
Shohet, RV ;
Black, S ;
Salmon, JE ;
Samols, D ;
Karp, DR ;
Thomas, GD ;
Shaul, PW .
CIRCULATION RESEARCH, 2005, 97 (11) :1124-1131
[25]   C-reactive protein inhibits endothelium-dependent nitric oxide-mediated dilation of retinal arterioles via enhanced superoxide production [J].
Nagaoka, Taiji ;
Kuo, Lih ;
Ren, Yi ;
Yoshida, Akitoshi ;
Hein, Travis W. .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2008, 49 (05) :2053-2060
[26]   C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice [J].
Paul, A ;
Ko, KWS ;
Li, L ;
Yechoor, V ;
McCrory, MA ;
Szalai, AJ ;
Chan, L .
CIRCULATION, 2004, 109 (05) :647-655
[27]   Targeting C-reactive protein for the treatment of cardiovascular disease [J].
Pepys, MB ;
Hirschfield, GM ;
Tennent, GA ;
Gallimore, JR ;
Kahan, MC ;
Bellotti, V ;
Hawkins, PN ;
Myers, RM ;
Smith, MD ;
Polara, A ;
Cobb, AJA ;
Ley, SV ;
Aquilina, JA ;
Robinson, CV ;
Sharif, I ;
Gray, GA ;
Sabin, CA ;
Jenvey, MC ;
Kolstoe, SE ;
Thompson, D ;
Wood, SP .
NATURE, 2006, 440 (7088) :1217-1221
[28]  
Pietila KO, 1996, EUR HEART J, V17, P1345
[29]   C-reactive protein inhibits endothelium-dependent NO-mediated dilation in coronary arterioles by activating p38 kinase and NAD(P)H oxidase [J].
Qamirani, E ;
Ren, Y ;
Kuo, L ;
Hein, TW .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (05) :995-1001
[30]   Clinical application of C-reactive protein for cardiovascular disease detection and prevention [J].
Ridker, PM .
CIRCULATION, 2003, 107 (03) :363-369